Navigation Links
PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
Date:3/17/2009

Offer and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, as soon as reasonably practicable after the completion of the Offer, Purchaser is expected to merge with and into PDGI (the "Merger"), with PDGI continuing as the surviving corporation and a wholly owned subsidiary of Parent. Given that the Offer and the Merger are each subject to a number of closing conditions, there can be no assurance that the Offer or the Merger will be completed on the expected dates.

The completion of the Offer will constitute a "Fundamental Change" under the terms of the Indenture for the Convertible Notes. Under the Indenture, in the event of a Fundamental Change prior to August 15, 2009, each holder of the Convertible Notes has the right to require PDGI, or its successor, to repurchase its Convertible Notes at a price equal to 100% of the principal amount outstanding, plus accrued and unpaid interest, plus a make-whole payment if certain thresholds are met. Since the price per share of the tender offer is $5.00, the holders of the Convertible Notes will not be entitled to a make-whole payment under the terms of the Indenture. Within 30 days following the Fundamental Change, PDGI, or its successor, will mail a notice, in accordance with the Indenture, to all holders indicating that a Fundamental Change has occurred and stating that the holders have the right described above.

This press release is being issued pursuant to the terms of the Indenture and, in connection with prior disclosure made by PDGI, is intended to give holders notice of the Anticipated Effective Date of the Fundamental Change. Given the uncertainty around the projected closing date of the Offer and the conditions applicable to the Offer and the Merger, the Company can not state with certainty if or when the Fundamental Change will occur. The Company does not anticipate that holders of the Convertible Notes will elect to convert becau
'/>"/>

SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
2. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
3. PharmaNet Development Group Agrees to be Acquired by JLL Partners
4. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
5. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
6. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
7. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
8. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
9. AMDL, Inc. Enters Into Collaboration Agreement to Advance Development of Its AMDL DR-70 (FDP) Cancer Test
10. Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia
11. AMPAC Fine Chemicals Announces the Inauguration of the New cGMP Continuous Processing Development Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Corp ., a non-profit development company that helps small businesses, ... technology businesses. , ,MDC said it has closed on loans ... off of Lucigen Corp. , and to BioSystem ... Contest. , ,C5-6 Technologies, which will develop enzymes used to ...
... series of articles on developing start-up companies in the technology or ... entity. , , Madison, Wis. - Now ... to the type of entity to use, you should have concerned ... people think of first. Income taxes depend upon the type of ...
... - Jim Rice, who has served as president and CEO ... the past year, will leave ITAWi after an agreed-upon transition ... organization announced. , ,ITAWi's Board of Director has begun ... will assume Rice's duties until a replacement is found. Rice ...
Cached Biology Technology:Early Stage: Step 6 - Taxes, taxes, taxes! 2Early Stage: Step 6 - Taxes, taxes, taxes! 3Early Stage: Step 6 - Taxes, taxes, taxes! 4Rice to leave Wisconsin technology association 2
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Virology of the GSF National Research Center for ... Research Centres) the group is continuing to search for ... of a prion infection. In collaboration with colleagues from ... Heidelberg, the group used micro-array technologies micro-arrays ...
... plant cell biologist at UC Riverside has received a ... investigate how plant stem-cells maintain their identity and how ... According to G. Venugopala Reddy, the principal investigator of ... on plants, has potential to lead to better insights ...
... infant formula-- may reduce a babys susceptibility to rotavirus ... a University of Illinois study published in Septembers Journal ... diarrhea in infants, affecting virtually all children before age ... dehydration, doctors visits, and parents missing work to care ...
Cached Biology News:Prions and retroviruses -- an unholy alliance? 2UCR plant cell biologist to study how plant stem cells maintain and change their identity 2Soy isoflavone may inhibit common gastrointestinal illness in infants 2
Request Info...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Blimp-1 (H-150)...
Biology Products: